Inventor · disambiguated record
Brandon Higgs
Also filed as: HIGGS BRANDON · HIGGS BRANDON W
6 granted patents·16 pending applications·17 citations·filing 2009–2023
78Inventor score
Top patents by PatentIndex Score
22 records- 0185US10829557B2Anti-B7-H1 antibodies for treating tumorsMEDIMMUNE LTD·Filed 2019·Granted Nov 10, 2020·2 cites·9 claims
- 0284US9493570B2Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodiesMEDIMMUNE LLC·Filed 2013·Granted Nov 15, 2016·8 cites·1 claims
- 0381US11016099B2Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkersAMGEN INC·Filed 2016·Granted May 25, 2021·3 cites·22 claims
- 0477US11220541B2CCL20 as a predictor of clinical response to IL23-antagonistsAMGEN INC·Filed 2016·Granted Jan 11, 2022·1 cites·32 claims
- 0576US10336823B2Anti-B7-H1 antibodies for treating tumorsMEDIMMUNE LTD·Filed 2014·Granted Jul 2, 2019·3 cites·18 claims
- 0669US11827706B2Anti-B7-H1 antibodies for treating tumorsMEDIMMUNE LTD·Filed 2020·Granted Nov 28, 2023·0 cites·20 claims
- 0769US2023145764A1Blood-based tumor mutation burden predicts overall survival in nsclcMEDIMMUNE LLC·Filed 2022·Application pending·0 cites
- 0863US2022144935A1Ccl20 as a predictor of clinical response to il23-antagonistsAMGEN INC·Filed 2021·Application pending·0 cites
- 0963US2020190598A1Blood-based tumor mutation burden predicts overall survival in nsclcMEDIMMUNE LLC·Filed 2019·Application pending·0 cites
- 1061US2024150469A1Anti-b7-h1 antibodies for treating tumorsMEDIMMUNE LTD·Filed 2023·Application pending·0 cites
- 1154US2023193399A1Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinomaASTRAZENECA AB·Filed 2021·Application pending·0 cites
- 1253US2022373539A1Prediction of clinical response to il23-antagonists using il23 pathway biomarkersAMGEN INC·Filed 2021·Application pending·0 cites
- 1352US2024327544A1Multispecific binding agents against cd40 and cd137 in combination therapy for cancerBioNTech SE·Filed 2022·Application pending·0 cites
- 1448US2011262928A1Disease markers and uses thereofMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 1546US2016024205A1Type I Interferon DiagnosticMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
- 1645US2012251546A1Type 1 inteferon diagnosticHIGGS BRANDON·Filed 2010·Application pending·0 cites
- 1744US2015191788A1Type 1 interferon diagnosticMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
- 1841US2018282417A1Tumor burden as measured by cell free dnaMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 1939US2017275347A1Methods for identifying patients responsive to anti-pd-l1 antibody therapyMEDIMMUNE LTD·Filed 2015·Application pending·0 cites
- 2038US2018079814A1Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancerMEDIMMUNE LTD·Filed 2016·Application pending·0 cites
- 2135US2018364240A1Methods for treatment and selection of patients responsive to immune mediated cancer therapyMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 2235US2019256603A1Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancerMEDIMMUNE LLC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Brandon Higgs files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →